Valeant Pharmaceuticals (VRX) Target Raised to $120 at Jefferies on B&L Deal
Tweet Send to a Friend
Jefferies boosted its price target on Valeant Pharmaceuticals (NYSE: VRX) from $77 to $120 after the company's deal to acquire ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
